Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1471-2407

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study ; volume:22 ; number:1 ; day:11 ; month:5 ; year:2022 ; pages:1-11 ; date:12.2022
BMC cancer ; 22, Heft 1 (11.5.2022), 1-11, 12.2022

Creator: Kawai, Akira
Narahara, Hiroyuki
Takahashi, Shunji
Nakamura, Tomoki
Kobayashi, Hiroshi
Megumi, Yasunori
Matsuoka, Toshiyuki
Kobayashi, Eisuke

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-022-09527-y

URN: urn:nbn:de:101:1-2022071707335825743159

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:29 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kawai, Akira
Narahara, Hiroyuki
Takahashi, Shunji
Nakamura, Tomoki
Kobayashi, Hiroshi
Megumi, Yasunori
Matsuoka, Toshiyuki
Kobayashi, Eisuke
SpringerLink (Online service)

Other Objects (12)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

Eribulin drug review

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy

Eribulin: Nutzenbewertung gemäß § 35a SGB V

Eribulin (Addendum zum Auftrag A14-25)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

Eribulin drug review

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy

Eribulin: Nutzenbewertung gemäß § 35a SGB V

Eribulin (Addendum zum Auftrag A14-25)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

Eribulin drug review

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy

Eribulin: Nutzenbewertung gemäß § 35a SGB V

Eribulin (Addendum zum Auftrag A14-25)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

Eribulin drug review

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy

Eribulin: Nutzenbewertung gemäß § 35a SGB V

Eribulin (Addendum zum Auftrag A14-25)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

Eribulin drug review

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy

Eribulin: Nutzenbewertung gemäß § 35a SGB V

Eribulin (Addendum zum Auftrag A14-25)

Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

Eribulin drug review

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin

Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes

Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy

Eribulin: Nutzenbewertung gemäß § 35a SGB V

Eribulin (Addendum zum Auftrag A14-25)

Related objects

Reset password